Innovative Nanobodies: A New Approach to Combat COVID-19
Written on
Introduction to Nanobodies
Researchers are on a mission to develop a range of nano-scale solutions in the ongoing battle against COVID-19. These innovative molecules, referred to as nanobodies, have gained attention for their unique characteristics that make them strong candidates for combating viral infections. A significant advancement in this field has been achieved by scientists at the University of Zurich, who have established a platform capable of rapidly generating extensive libraries of nanobodies and selecting those that exhibit the highest potential for neutralizing the virus. Collaborating with industry partner Absolute Antibody, these researchers are working swiftly to deliver their promising discoveries to the global populace.
Understanding Nanobodies
Nanobodies, or single-domain antibodies, are diminutive protein fragments that can specifically bind to targets, such as viral proteins. Measuring only a tenth of the size of conventional antibodies, nanobodies offer notable advantages for clinical use: they can access areas of the body that were previously unreachable and are simpler to produce in large quantities. These nanobodies are modeled after a specific type of antibody found in the immune systems of camels, llamas, and alpacas, known as VHH fragments. Current investigations are examining their potential applications in treating conditions like cancer and Alzheimer’s disease.
Potential for COVID-19 Treatment
Researchers are particularly focused on how nanobodies can be utilized to combat COVID-19, as they could potentially be administered through inhalation. An inhalable spray would target the lungs of infected individuals far more rapidly than traditional antibody therapies, which typically require intravenous administration. The lab of Markus Seeger has developed a research tool to discover synthetic nanobodies that bind to the receptor-binding domain (RBD) of SARS-CoV-2. Prior studies indicate that blocking this RBD region can impede the virus's ability to invade lung cells and exacerbate COVID-19 symptoms. Remarkably, in just two weeks, Seeger’s lab identified over 60 distinct RBD-blocking nanobodies using their innovative platform.
Collaboration for Greater Impact
The team is joining forces with Absolute Antibody, leveraging their expertise in the engineering and mass production of antibodies for clinical applications. “Partnering with Absolute Antibody has allowed us to broaden the scope and applications of our novel synthetic nanobodies, enhancing their potential in the urgent quest for effective therapeutics,” noted Seeger. Furthermore, nanobodies could significantly mitigate the dire consequences of the pandemic, serving not only as therapeutic agents but also playing a vital role in COVID-19 diagnostics.
This video explores the development of nanobodies as a promising approach to combat COVID-19, highlighting their unique properties and applications.
In this video, experts discuss the science behind aerosolized nanobodies and their potential for passive immunization against SARS-CoV-2.